14 studies found for:    Open Studies | "Thymus Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Conditions: Thymoma;   Thymus Neoplasms
Intervention: Drug: Sunitinib
2 Recruiting Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
Condition: Thymoma
Intervention: Radiation: radiotherapy
3 Recruiting Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Condition: Malignant Thymoma
Intervention: Drug: Milciclib Maleate
4 Recruiting A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Condition: Thymoma
Intervention: Drug: BKM120
5 Recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Conditions: Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
6 Recruiting Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Conditions: Lymphoma;   Malignant Mesothelioma;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Soft Tissue Sarcoma;   Thymoma and Thymic Carcinoma
Interventions: Drug: doxepin hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory procedure
7 Recruiting Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Conditions: Lung Metastases;   Recurrent Malignant Mesothelioma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Thymoma and Thymic Carcinoma
Intervention: Radiation: proton beam radiation therapy
8 Recruiting Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: Milciclib Maleate
9 Recruiting Nonmyeloablative Allogeneic Transplant
Conditions: Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
Intervention: Procedure: Nonmyeloablative Allogeneic Transplant
10 Recruiting Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue
Conditions: Thymus Tumors;   Mesothelioma;   Non- Small Cell Lung Cancer;   Small Cell Lung Cancer
Intervention:
11 Not yet recruiting MK-3475 in Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: MK-3475
12 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Intervention:
13 Recruiting Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
Condition: Locally Advanced Stage III or IV Thymic Cancer
Intervention: Drug: neoadjuvant docetaxel/cisplatin
14 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma
Intervention:

Indicates status has not been verified in more than two years